New Frontiers of Treatment for Mitral Valve Disease

Click Here to Watch the Webinar »


Martin B. Leon

Director, Center for Interventional Vascular Therapy
Professor of Clinical Medicine, CUMC


Michael Argenziano, MD

Chief, Adult Cardiac Surgery Section
Associate Professor of Surgery at CUMC

Michael A. Borger, MD

Director of Cardiovascular Institute and Director of Aortic Program
George Humphries II Professor of Surgery

William A. Gray, MD

Director, Endovascular Services
Assistant Professor of Clinical Medicine, CUMC

Program Description

New Frontiers of Treatment for Mitral Valve Disease is a non-CME evening webinar discussion, which will focus on education leading to improved patient care and better outcomes.

Target Audience

This activity is designed for surgeons, general surgeons, primary care physicians, interventional cardiologists and clinical cardiologists.

Educational Needs Assessment

The current preferred treatment for mitral valve disease is mitral valve surgery which leads to an improved quality of life and expanded life expectancy as the flow to the heart becomes regulated.  

With the success of a minimally invasive transcatheter approach to aortic valve replacement, TAVR, similar strategies are being applied to mitral valve replacement and repair.   The MitraClip device, for example is available for patients with significant symptomatic degenerative mitral regurgitation and are too high risk for surgery. In this procedure, a metal clip is advanced on a catheter delivery system through the femoral vein to the heart, clipping the leaflets together.  Several devices emulating the TAVR device are in early stages of clinical trials and provide great promised for those who are not good candidates for surgery.

This program will examine the now and the near and distant future of Mitral Valve treatment and its bright future.

Learning Objectives

At the end of this program, the attendees will be able to:

  • Describe landscape current and future mitral valve therapies
  • Identify the appropriate therapies for different patient subsets